DEALS: Crucell bids for lead vaccine role

DEALS

WHO

WITH

WHAT

SCOOP

Crucell

Berna Biotech

$449 million buyout offer

Crucell is making a bid to become the leading independent vaccine player in the world.

Cephalon

Zeneus Pharma

$360 million acquisition

The acquisition spurs Cephalon's entry into the European oncology market.

Phase III Medical

Neostem

Acquisition

Phase III gains a company that specializes in the collection and storage of adult stem cells.

Matrix Laboratories

Concord Biotech

Acquisition of majority stake

Concord has fermentation and bio-catalytic technology capabilities.

Molecular Pharmacology

Molecular Pharmacology Limited

Acquisition

The acquisition of MPL Australia will provide MPL USA a broader international arena.